STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
Moberg Derma AB (STO:MOB):
HALF YEAR (JAN-JUN 2012)
• Revenue MSEK 55.5 (13.5)
• Research and development expenses MSEK 15.9 (13.7)
• Operating profit MSEK 9.3 (-16.3)
• Net profit after tax MSEK 39.4 (-16.2)